Kalydeco has been approved by the Food And Drug Administration (FDA) to treat a vicious type of Cystic Fibrosis (CF). CF is a deadly recessive disease which targets the lungs, but can also harm the liver, pancreas, and intestine. It occurs from the unusual transport of chloride and sodium across the epithelium, causing […]
Filed under: Cystic Fibrosis on February 1st, 2012 | No Comments »
The lung clearance index (LCI) is a sensitive non-invasive marker of early lung disease in young children with cystic fibrosis (CF), according to a new study from Australian researchers…
More: continued here
Filed under: Cystic Fibrosis on January 31st, 2012 | No Comments »
According to a new Australian study published online before he print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, the lung clearance index (LCI) is a sensitive, non-invasive marker of early lung disease in young children with cystic fibrosis (CF)…
More: continued here
Filed under: Cystic Fibrosis on January 30th, 2012 | No Comments »
With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug…
More: continued here
Filed under: Cystic Fibrosis on January 21st, 2012 | No Comments »
Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…
More: continued […]
Filed under: Cystic Fibrosis on December 20th, 2011 | No Comments »
Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…
More: continued […]
Filed under: Cystic Fibrosis on December 20th, 2011 | No Comments »
A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy administration of the treatment might help enhance adherence with treatment in individuals suffering with the condition…
More: continued […]
Filed under: Cystic Fibrosis on December 20th, 2011 | No Comments »
Researchers at Harvard Medical School and Children’s Hospital Boston have retraced the evolution of an unusual bacterial infection as it spread among cystic fibrosis patients by sequencing scores of samples collected during the outbreak, since contained…
More: continued here
Filed under: Cystic Fibrosis on November 16th, 2011 | No Comments »
Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medication ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other signs and symptoms for cystic fibrosis (CF) patients…
More: continued here
Filed under: Cystic Fibrosis on November 6th, 2011 | No Comments »
A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, “A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation,” led by Bonnie W…
More: continued here
Filed under: Cystic Fibrosis on November 6th, 2011 | No Comments »